Skip to main content
letter
. 2020 Jun 16;190(2):e117–e120. doi: 10.1111/bjh.16762

Table I.

Best objective tumour response.

Pembrolizumab

n = 23

Objective response rate, n (%) [95% CI] 3 (13·0) [2·8–33·6]
Best objective response, n (%)
Complete response 1 (4·3)
Partial response 2 (8·7)
Stable disease 1 (4·3)
Progressive disease 11 (47·8)
No assessment a 8 (34·8)

CI, confidence interval.

a

Patients with no assessment either died or discontinued the study without having had imaging performed.